Abstract:Cervical cancer stands as a prevalent gynaecologic malignancy affecting women globally, often linked to persistent human papillomavirus infection. Biomarkers associated with cervical cancer, including VEGF-A, VEGF-B, VEGF-C, VEGF-D, and VEGF-E, show upregulation and are linked to angiogenesis and lymphangiogenesis. This research aims to employ in-silico methods to target tyrosine kinase receptor proteins—VEGFR-1, VEGFR-2, and VEGFR-3, and identify novel inhibitors for Vascular Endothelial Growth Factors receptors (VEGFRs). A comprehensive literary study was conducted which identified 26 established inhibitors for VEGFR-1, VEGFR-2, and VEGFR-3 receptor proteins. Compounds with high-affinity scores, including PubChem ID—25102847, 369976, and 208908 were chosen from pre-existing compounds for creating Deep Learning-based models. RD-Kit, a Deep learning algorithm, was used to generate 43 million compounds for VEGFR-1, VEGFR-2, and VEGFR-3 targets. Molecular docking studies were conducted on the top 10 molecules for each target to validate the receptor-ligand binding affinity. The results of Molecular Docking indicated that PubChem IDs—71465,645 and 11152946 exhibited strong affinity, designating them as the most efficient molecules. To further investigate their potential, a Molecular Dynamics Simulation was performed to assess conformational stability, and a pharmacophore analysis was also conducted for indoctrinating interactions.

What problem does this paper attempt to address?

### Problems the paper attempts to solve This paper aims to develop new inhibitors targeting vascular endothelial growth factor receptors (VEGFR1, VEGFR2 and VEGFR3) through deep - learning methods for the treatment of cervical cancer. Specifically, the research objectives include: 1. **Identify potential VEGFR inhibitors**: - Through literature review, 26 known highly effective inhibitors of VEGFR1, VEGFR2 and VEGFR3 were screened out. - Use deep - learning algorithms to generate a large number of compounds and screen out high - affinity candidate molecules from them. 2. **Verify the binding affinity of candidate molecules**: - Through molecular docking technology, evaluate the binding affinity of the top 10 candidate molecules with the target receptors. - Select several compounds with the highest binding affinity for further study. 3. **Evaluate the stability and pharmacological properties of candidate molecules**: - Conduct molecular dynamics simulation to evaluate the conformational stability of candidate molecules in the bound state. - Through pharmacophore analysis and ADMET (absorption, distribution, metabolism, excretion and toxicity) studies, evaluate the pharmacological properties and safety of candidate molecules. 4. **Compare the performance of new and old inhibitors**: - Compare the newly discovered candidate molecules with known highly effective inhibitors to evaluate their advantages and disadvantages in terms of binding affinity, stability and pharmacological properties. ### Background and significance Cervical cancer is a common gynecological malignant tumor, mainly caused by human papillomavirus (HPV) infection. Biomarkers of the VEGF family (such as VEGF - A, VEGF - B, VEGF - C, VEGF - D and VEGF - E) are up - regulated in cervical cancer and are involved in angiogenesis and lymphangiogenesis. VEGFR1, VEGFR2 and VEGFR3, as tyrosine kinase receptors, initiate autophosphorylation and dimerization after ligand binding, activating intracellular signaling pathways and promoting vascular permeability and angiogenesis. Traditional treatment methods (such as surgery, radiotherapy and chemotherapy) are complex and have side effects, so the development of new targeted drugs is of great significance. Small - molecule compounds, as tyrosine kinase inhibitors, can competitively bind to the ligand - binding sites of angiogenic factors, blocking angiogenesis, and thus become a potential strategy for the treatment of cervical cancer. ### Methods and techniques 1. **Literature review and compound screening**: - Through literature review, 26 known VEGFR inhibitors were screened out. - Use RDKit and deep - learning algorithms to generate a library of 43 million compounds. 2. **Molecular docking**: - Use Molegro Virtual Docker software for molecular docking to evaluate the binding affinity of candidate molecules with VEGFR1, VEGFR2 and VEGFR3. - Select the top 10 compounds with the highest binding affinity for further study. 3. **Molecular dynamics simulation**: - Use Schrodinger's Desmond module to conduct a 100 - nanosecond molecular dynamics simulation to evaluate the conformational stability of candidate molecules in the bound state. 4. **Pharmacophore analysis and ADMET studies**: - Through pharmacophore analysis, evaluate the interaction patterns of candidate molecules. - Use the AdmetSAR server for ADMET prediction to evaluate the pharmacological properties and safety of candidate molecules. ### Results and discussion - **Molecular docking results**: - Several compounds with the highest binding affinity were screened out, such as PubChem ID 71465645, 11152946 and 1115294, and these compounds showed excellent performance in terms of binding affinity. - **Molecular dynamics simulation results**: - The simulation results showed that these candidate molecules had good conformational stability in the bound state, especially in the VEGFR1:71465645 complex. - **Pharmacophore analysis and ADMET study results**: - The candidate molecules showed good interaction patterns in the pharmacophore analysis and showed low...

Potential inhibitors of VEGFR1, VEGFR2, and VEGFR3 developed through Deep Learning for the treatment of Cervical Cancer

Identification of Phytochemical Inhibitors Targeting VEGFA and TGFBR2 of Cervical Cancer: Insights from Virtual Screening, ADMET and DFT Studies

3D physiologically-informed deep learning for drug discovery of a novel vascular endothelial growth factor receptor-2 (VEGFR2)

Pharmacophore Based Virtual Screening for Identification of Effective Inhibitors to Combat HPV 16 E6 Driven Cervical Cancer.

Molecular docking aided machine learning for the identification of potential VEGFR inhibitors against renal cell carcinoma

From deep learning to the discovery of promising VEGFR‐2 inhibitors

Discovery of VEGFR2 inhibitors by integrating naïve Bayesian classification, molecular docking and drug screening approaches

Identification of Novel Potential VEGFR-2 Inhibitors Using a Combination of Computational Methods for Drug Discovery

Structure-Based Virtual Screening, Molecular Docking, and Molecular Dynamics Simulation of VEGF inhibitors for the clinical treatment of Ovarian Cancer

Identifying novel and potent inhibitors of EGFR protein for the drug development against the breast cancer

Virtual screening, molecular dynamics simulations, and in vitro validation of EGFR inhibitors as breast cancer therapeutics

Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies

Design, synthesis, and in silico insights of novel N'-(2-oxoindolin-3-ylidene)piperidine-4-carbohydrazide derivatives as VEGFR-2 inhibitors

In Silico Repurposing of a Novel Inhibitor (drug) of EGFR and VEGFR-2 Kinases of Cancer by Pharmacokinetics, Toxicity, Molecular Docking, and Molecular Dynamics Simulation

In Silico Screening of 1,3,4-Thiadiazole Derivatives as Inhibitors of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2)

In Silico Exploration of Novel EGFR Kinase Mutant-Selective Inhibitors Using a Hybrid Computational Approach

Discovery, Synthesis, and Evaluation of Highly Selective Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Inhibitor for the Potential Treatment of Metastatic Triple-Negative Breast Cancer

Inhibition of Vascular Smooth Muscle and Cancer Cell Proliferation by New VEGFR Inhibitors and Their Immunomodulator Effect: Design, Synthesis, and Biological Evaluation

Receptor-based pharmacophore modeling, molecular docking, synthesis and biological evaluation of novel VEGFR-2, FGFR-1, and BRAF multi-kinase inhibitors

Bioinformatics Screening of Potential Biomarkers from mRNA Expression Profiles to Discover Drug Targets and Agents for Cervical Cancer

Exploratory drug discovery in breast cancer patients: A multimodal deep learning approach to identify novel drug candidates targeting RTK signaling